STOCK TITAN

Oruka Therapeutics CMO sells 7,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. Chief Medical Officer Joana Goncalves exercised 3,500 employee stock options at $6.84 and 3,500 employee warrants at $7.80 on November 16, 2026, acquiring 7,000 common shares. She also sold 7,000 common shares that day in six reported sale entries, at weighted-average prices from $99.5150 to $105.8560 per share. The sales were effected under a Rule 10b5-1 trading plan entered into on September 19, 2025.

Insider Goncalves Joana
Role Chief Medical Officer
Sold 7,000 shs ($707K)
Approx. gross sale proceeds $707K
Approx. exercise cost $51K
Approx. pre-tax spread $655K
Share of Position Sold 18.1%
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F8 3,500 $0.00 $0.00
Exercise Employee Warrant (right to buy) F9 3,500 $0.00 $0.00
Exercise Common Stock 3,500 $6.84 $24K
Exercise Common Stock 3,500 $7.80 $27K
Sale Common Stock F1, F2 2,600 $99.515 $259K
Sale Common Stock F1, F3 1,500 $100.4792 $151K
Sale Common Stock F1, F4 1,900 $101.5268 $193K
Sale Common Stock F1, F5 300 $102.47 $31K
Sale Common Stock F1, F6 200 $103.36 $21K
Sale Common Stock F1, F7 500 $105.856 $53K
Holdings After Transaction: Employee Stock Option (right to buy) — 186,563 options (Direct); Employee Warrant (right to buy) — 157,992 warrants (Direct); Common Stock — 31,771 shares (Direct)
Holdings Before and After: Employee Stock Option (right to buy), 190,063 to 186,563 options (Direct); Employee Warrant (right to buy), 161,492 to 157,992 warrants (Direct); Common Stock, 31,771 to 31,771 shares (Direct)
Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (9)
  1. F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.03 to $99.98, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.11 to $101.04, inclusive.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.11 to $102.09, inclusive.
  5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.18 to $102.95, inclusive.
  6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.26 to $103.46, inclusive.
  7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.48 to $106.20, inclusive.
  8. F8. The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
  9. F9. The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
Common shares sold 7,000 shares Reported on November 16, 2026, across six sale entries
Weighted-average sale prices $99.5150–$105.8560 per share Lowest to highest weighted-average price among six sale entries on November 16, 2026
Employee stock options exercised 3,500 shares November 16, 2026; exercise price $6.84 per share
Option exercise price $6.84 per share Employee stock options exercised November 16, 2026
Employee warrants exercised 3,500 shares November 16, 2026; exercise price $7.80 per share
Warrant exercise price $7.80 per share Employee warrants exercised November 16, 2026
Employee stock options following transaction 186,563 options Reported after the November 16, 2026 exercise
Employee warrants following transaction 157,992 warrants Reported after the November 16, 2026 exercise
Rule 10b5-1 trading plan regulatory
"the sales of 7,000 shares under a plan entered into on September 19, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"prices reported for the six common-stock sale entries"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Option (right to buy) financial
"the exercise of 3,500 options at $6.84 per share"
Employee Warrant (right to buy) financial
"the exercise of 3,500 warrants at $7.80 per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORKA shares did Joana Goncalves sell, and at what prices?

Joana Goncalves sold 7,000 Oruka Therapeutics common shares on November 16, 2026, across six reported entries whose weighted-average prices ranged from $99.5150 to $105.8560 per share. The sales were effected under a Rule 10b5-1 trading plan entered into on September 19, 2025.

What options and warrants did ORKA's chief medical officer exercise?

Joana Goncalves exercised 3,500 employee stock options at $6.84 per share and 3,500 employee warrants at $7.80 per share on November 16, 2026. The reported post-transaction positions were 186,563 options and 157,992 warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Goncalves Joana

(Last)(First)(Middle)
C/O ORUKA THERAPEUTICS, INC.
855 OAK GROVE AVE., SUITE 100

(Street)
MENLO PARK CALIFORNIA 94025

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M3,500A$6.8435,271D
Common Stock11/16/2026M3,500A$7.838,771D
Common Stock11/16/2026S(1)2,600D$99.515(2)36,171D
Common Stock11/16/2026S(1)1,500D$100.4792(3)34,671D
Common Stock11/16/2026S(1)1,900D$101.5268(4)32,771D
Common Stock11/16/2026S(1)300D$102.47(5)32,471D
Common Stock11/16/2026S(1)200D$103.36(6)32,271D
Common Stock11/16/2026S(1)500D$105.856(7)31,771D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$6.8411/16/2026M3,500 (8)05/06/2034Common Stock3,500$0186,563D
Employee Warrant (right to buy)$7.811/16/2026M3,500 (9)07/14/2034Common Stock3,500$0157,992D
Explanation of Responses:
1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.03 to $99.98, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.11 to $101.04, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.11 to $102.09, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.18 to $102.95, inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.26 to $103.46, inclusive.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.48 to $106.20, inclusive.
8. The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
9. The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
/s/ Paul Quinlan, as attorney-in-fact for Joana Goncalves11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading